AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Every year, we hold a STAT Madness tournament to find the best ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...

North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

AbbVie (ABBV) on Monday said it struck a licensing deal with Danish biotechnology company Gubra to develop a potential candidate for obesity treatment. AbbVie will be responsible for the global ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Gubra And AbbVie - AbbVie and Gubra A/S have entered into a licensing agreement to develop GUB014295, a promising long-acting ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...